Thymopentin treatment of rheumatoid arthritis.
E Sundal, D Bertelletti
Index: Arzneimittelforschung 44(10) , 1145-9, (1994)
Full Text: HTML
Abstract
Although the etiology of rheumatoid arthritis (RA) is unknown, there is solid evidence that immunological factors play a pivotal role in its pathogenesis. It seems that a hyporeactivity of local (intraarticular) T-suppressor cells would permit an excessive immune response that ultimately leads to the classical symptoms and signs of inflammation and cartilage damage. Thymopentin is a synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) which represents the active biologic site (sequence 32-36) of the native thymic hormone thymopoietin, containing 49 amino acids. Thymopoietin and thymopentin have been shown to possess immuno-normalizing properties in a number of animal model systems. Low concentrations of the hormone characteristically stimulate the OKT4-positive cells, whereas higher concentrations additionally induce stimulation of OKT8-positive cells. This report summarizes the clinical experience collected by Italian investigators, and discusses the results with a view to previously published papers.
Related Compounds
Related Articles:
2012-05-10
[Int. J. Pharm. 427(2) , 385-92, (2012)]
2015-01-01
[J. Pharm. Biomed. Anal. 102 , 137-43, (2014)]
1991-01-01
[Minerva Ginecol. 43(1-2) , 53-6, (1991)]
1999-06-01
[Pharm. Acta Helv. 73(6) , 265-73, (1999)]
1989-01-01
[Med. Oncol. Tumor Pharmacother. 6(1) , 19-23, (1989)]